EUCTR2005-004853-86-IT进行中（未招募）不适用
Erythropoietin and ischaemic heart disease. - EPO and IHD
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI0 个研究点目标入组 123 人开始时间: 2006年1月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 123
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria for patients with AMI - continuous chest pain lasting 30 minutes but 6 hours; - 1mm ST-segment elevation on 2 ECG leads or new left bundle branch block; - planned treatment by primary percutaneous coronary angioplasty; - age 75 years; - signed informed consent. Inclusion criteria for patients with CSA - significant coronary artery disease at angiography; - maximal drug therapy; - inducible ischaemia on exercise testing; - no indication to undergo percutaneous or surgical coronary revascularisation; - age 75 years; - signed informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria for patients with AMI - previous myocardial infarction; - previous thrombolysis or treatment with EPO; - previous cerebrovascular event; - uncontrolled hypertension; - hematocrit 48 in men and 45 in women; - haemoglobin 16 g/dl in men and 15 g/dl in women; - major surgery, major trauma or blood transfusions in the previous 6 weeks; - current oral anticoagulant therapy; - allergy to aspirin; - renal, lung or liver failure; - myeloproliferative diseases or malignancies; - possible or known pregnancy; - participation in other clinical randomised trial; - pacemaker in situ. Exclusion criteria for patients with CSA - previous treatment with EPO; - previous cerebrovascular event; - uncontrolled hypertension; - hematocrit 48 in men and 45 in women; - haemoglobin 16 g/dl in men and 15 g/dl in women; - major surgery, major trauma or blood transfusions in the previous 6 weeks; - current oral anticoagulant therapy; - allergy to aspirin; - renal, lung or liver failure; - myeloproliferative diseases or malignancies; - possible or known pregnancy; - participation in other clinical randomised trial; - percutaneous or surgical coronary revascularisation in the previous 6 months; - pacemaker in situ.
研究者
相似试验
已完成
不适用
Effect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischaemic strokeStrokeISRCTN71371114ational Science Council (Taiwan)220
已完成
3 期
Evaluation of Erythropoietin's effect in patients consciousnessTraumatic Brain Injury.Other specified intracranial injury with loss of consciousness of unspecified durationS06.899IRCT20190429043416N1Tehran University of Medical Sciences18
已完成
不适用
The use of erythropoietin in cardiac surgery to protect against ischaemia-related injury in kidney and other organ systemsISRCTN89080534HS Greater Glasgow and Clyde (UK)84
已完成
不适用
Erythropoietin effect on ischemic_reperfusion injuryIschemic reperfusion injury in chronic artery bypass graft surgery.Chronic ischaemic heart diseaseI25.1,I25.IRCT2016011621087N1Pooyesh Darou company and Shahid Beheshti University of Medical Sciences90
撤回
不适用
Cardioprotective Effects of Increased Endogenous Erythropoietin After Normobaric Oxygen BreathingHealthyCoronary Artery Bypass GraftNCT00824759Cliniques universitaires Saint-Luc- Université Catholique de Louvain